# VOYAGE (NCT02152956)

> Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

No report yet. It can be ordered.

- Drugs tested: flotetuzumab
- Indication: primary induction failure or early relapse AML

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02152956
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: MacroGenics
- Conditions: AML
- Interventions: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off; Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose; Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose; Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose; Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose; Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose; Ruxolitinib; Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose
- Enrollment: 244
- Primary outcome: Efficacy Based on CR or CRh Rate

## Indexed commentary on VOYAGE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=voyage-nct02152956